Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | UBE2N | P61088 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | LTK | P29376 | 1/20 | 0.50 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13220843 | 0.85 | RAB9A (0.53) | NR4A2PTPN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL12516120 | 0.84 | NR4A2 (0.61) | NR4A2PTPN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL28058838 | 0.82 | NR4A2 (0.50) | NR4A2PTPN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL8422956 | 0.81 | NR4A2 (0.60) | NR4A2PTPN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL11562469 | 0.79 | NR4A2 (0.63) | NR4A2PTPN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL13929701 | 0.79 | NR4A2 (0.63) | NR4A2PTPN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL6326819 | 0.79 | NR4A2 (0.63) | NR4A2PTPN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL5510087 | 0.78 | NR4A2 (0.61) | NR4A2PTPN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL13220854 | 0.77 | ALDH1A1 (0.64) | KMT2AALDH1A1MEN1MAPTL3MBTL1 | |
| SCHEMBL7113042 | 0.77 | MAOB (0.47) | NR4A2PTPN1KMT2AALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017042099-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | BASILEA PHARMACEUTICA AG (CH) | 2017-03-16 | — | — | WO | disclosed |
| US-9296711-B2 | Substituted isoxazole amide compounds as inhibitors of stearoyl-CoA desaturase 1 (SCD1) | HOFFMAN-LA ROCHE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150307463-A1 | SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1) | HOFFMANN-LA ROCHE INC. | 2015-10-29 | — | — | US | disclosed |
| EP-2925751-A1 | SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1) | F. Hoffmann-La Roche AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014086704-A1 | SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1) | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | disclosed |
| EP-0740654-B1 | MONOAMINE OXIDASE B INHIBITORS, PROCESSES FOR THEIR PREPARATION AND USE THEREOF | MAYOLY SPINDLER LAB (FR) | 1999-10-13 | — | — | EP | disclosed |
| US-5811456-A | TREATMENT OF ALZHEIMER'S DISEASE | LABORATOIRES MAYOLY SPINDLER (FR) | 1998-09-22 | — | — | US | disclosed |
| EP-0740654-A1 | MONOAMINE OXIDASE B INHIBITORS, PROCESSES FOR THEIR PREPARATION AND USE THEREOF | LABORATOIRES MAYOLY SPINDLER (FR) | 1996-11-06 | — | — | EP | disclosed |
| WO-1995019960-A1 | MONOAMINE OXIDASE B INHIBITORS, PROCESSES FOR THEIR PREPARATION AND USE THEREOF | LABORATOIRES MAYOLY SPINDLER (FR) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307463-A1 | SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1) | SCD, SCD5, CPT1A | NR4A2 3511/4885PTPN1 3835/4885KMT2A 2886/4885 |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, KCNB2, SCNN1B | NR4A2 1469/4885PTPN1 3286/4885KMT2A 2744/4885 |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, SCNN1B, TRPV1 | NR4A2 2118/4885PTPN1 2977/4885KMT2A 3151/4885 |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | S1PR5, LPAR5, S1PR1 | NR4A2 1522/4885PTPN1 2289/4885KMT2A 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.